## DHR: Danaher Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 0.8% below STRENGTH zone (4.0-10.0%); PEG 1.94 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: declining volume (47% of avg).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($222.28)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 9
- **Sentiment:** Neutral (Bullish: 2, Bearish: 0)

**1. HALPER SADEH LLC ENCOURAGES DANAHER CORPORATION SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS**
- Source: PR Newswire | 20251224T165004 | Somewhat-Bearish | Relevance: 100%
- Halper Sadeh LLC, an investor rights law firm, is investigating potential breaches of fiduciary duties by certain officers and directors of Danaher Corporation (NYSE: DHR). Long-term shareholders are encouraged to contact the firm to learn about their legal rights and options, which may include seeking corporate governance reforms or financial relief. The firm emphasizes that shareholder involvement can lead to improved corporate policies and increased shareholder value.

**2. Can Mixed Fundamentals Have A Negative Impact on Danaher Corporation (NYSE:DHR) Current Share Price Momentum?**
- Source: 富途牛牛 | 20251223T001142 | Somewhat-Bearish | Relevance: 100%
- Danaher's stock has risen by 19% in the last three months, but an analysis of its fundamentals shows mixed signals regarding its financial health. The company's Return on Equity (ROE) of 6.9% is lower than the industry average of 11%, coinciding with a 5-year net income decline of 5.6%. Although Danaher retains a significant portion of its earnings (81% retention ratio), this has not translated into earnings growth, suggesting potential headwinds or issues with capital allocation, despite future analyst predictions for earnings growth.

**3. Danaher Corp. stock outperforms competitors on strong trading day**
- Source: MarketWatch | 20251222T163600 | Bullish | Relevance: 100%
- Danaher Corp. (DHR) stock increased by 1.41% to $228.01, outperforming the S&P 500 Index and the Dow Jones Industrial Average on a strong trading day. This marks the third consecutive day of gains for the company's stock. The robust performance comes amidst a positive overall market session.

**4. Ex-Dividend Reminder: Medtronic, Danaher and DENTSPLY SIRONA**
- Source: Nasdaq | 20251224T150750 | Neutral | Relevance: 100%
- Medtronic PLC (MDT), Danaher Corp (DHR), and DENTSPLY SIRONA Inc (XRAY) are set to trade ex-dividend on December 26, 2025. Investors can expect their shares to open lower by 0.73%, 0.14%, and 1.44% respectively, reflecting their upcoming dividend payments. The article provides current estimated annual yields and historical dividend charts for each company.

**5. James Hambro & Partners LLP Lowers Stock Holdings in Danaher Corporation $DHR**
- Source: MarketBeat | 20251224T134109 | Neutral | Relevance: 100%
- James Hambro & Partners LLP significantly reduced its stake in Danaher Corporation by 48.5% in Q3, now holding 150,904 shares valued at $29.9 million. This adjustment makes Danaher its 21st biggest position, representing 1.1% of its portfolio. Various other institutional investors have also recently adjusted their holdings in Danaher, which reported strong Q3 earnings, beating analyst expectations.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | Wells Fargo | $240 | $230 | +4% |
| 2025-12-09 | Goldman Sachs | $265 | $0 | 0% |
| 2025-12-02 | Morgan Stanley | $270 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | Wells Fargo | main | Equal-Weight |
| 2025-12-09 | Goldman Sachs | init | Buy |
| 2025-12-02 | Morgan Stanley | init | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 8 ($0.20M) |
| Sells | 10 ($75.99M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 37.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 8.6% (+0.2%)
- Blackrock Inc.: 7.4% (+0.1%)
- JPMORGAN CHASE & CO: 5.3% (+404.7%)
- State Street Corpora: 3.9% (-0.3%)
- Capital Internationa: 2.4% (+1.9%)

### Key Risks

1. Heavy insider selling: $76M sold (10 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Momentum building: MRS_20 improving +1.1% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.94 elevated, pricing in significant growth expectations. Forward P/E 27.5x stretched relative to 9% growth. Balance sheet: $1.4B free cash flow. Insider selling cluster ($76.0M in 90 days), potential headwind. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $165.7B |
| Beta | 0.92 |
| 52W Range | $171.00 - $258.23 |
| Short Interest | 1.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.94 |
| Forward P/E | 27.5 |
| Current P/E | 30.0 |
| YoY Growth | 9.1% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -0.3% to 0.8% (+1.1% in 5 days), confirming momentum buildup. Below STRENGTH zone by 3.2pp (needs >4.0% for momentum thesis). MRS_5 at 0.5% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 60. Volume at 47% of 20MA suggests lack of conviction. OFD pattern: +MTL (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 0.81% (CS: 65) | Neutral |
| RSI_14 | 59.9 | Neutral |
| MACD Histogram | -0.10 | Bearish |
| vs SMA20 | 1.019x | Above |
| vs SMA50 | 1.045x | Above |
| vs SMA200 | 1.133x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $231.34
- **Stop Loss:** $222.28 (3.9% risk)
- **Target:** $240.40 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 132
- **Position Value:** $30,536.88
- **Portfolio %:** 30.54%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite supported by year-end positioning. VIX at cycle lows (13.47) and multiple sectors hitting 52-week highs indicate constructive sentiment, though breadth at 57.9% suggests selectivity remains important. Fed pause expectations and stable macro backdrop support risk assets.*

### Earnings

**Next:** 2026-01-28 (Est: $2.14)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.72 | $1.89 | +9.8% |
| 2025Q2 | $1.64 | $1.80 | +9.5% |
| 2025Q1 | $1.64 | $1.88 | +14.4% |
| 2024Q4 | $2.16 | $2.14 | -1.1% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*